EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide
Authors:
- Manuela CominelliMCManuela Cominelli
- Salvatore GrisantiSGSalvatore Grisanti
- Stefania MazzoleniSMStefania Mazzoleni
- Caterina BrancaCBCaterina Branca
- Luciano ButtoloLBLuciano Buttolo
- Daniela FurlanDFDaniela Furlan
- Barbara LiserreBLBarbara Liserre
- Maria Fausta BonettiMBMaria Fausta Bonetti
- Daniela MedicinaDMDaniela Medicina
- Vilma PellegriniVPVilma Pellegrini
- Michela BuglioneMBMichela Buglione
- Roberto LiserreRLRoberto Liserre
Open Access
- 4 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (5)
Abstract
Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict. However, we identified patients with long-term survival (≥35 months) within a group of newly diagnosed GBM patients treated with standard or metronomic adjuvant temozolomide schedules. We thus investigated possible molecular profiles associated with longer survival following temozolomide treatment. We investigated the association of molecular features with progression-free (PFS) and overall survival (OS). Human-derived GBM cancer stem cells (CSCs) were used to investigate in vitro molecular mechanisms associated with temozolomide responsiveness. Surgically removed recurrences allowed investigation of molecular changes occurring during therapy in vivo. Statistical analyses included one- and two-way analysis of variance, Student’s t test, Cox proportional hazards, and the Kaplan-Meier method. All statistical tests were two-sided. No association was found between survival and gene classifiers associated with different molecular GBM subtypes in the standard-treated group, while in metronomic-treated patients robust association was found between EGFR amplification/overexpression and PFS and OS (OS, EGFR-high vs low: hazard ratiodeath = 0.22, 95% confidence interval = 0.09 to 0.55, P = .001). The result for OS remained statistically significant after Bonferroni correction (Pinteraction < .0005). Long-term survival following metronomic temozolomide was independent from MGMT and EGFRvIII status and was more pronounced in EGFR-overexpressing GBM patients with PTEN loss. In vitro findings confirmed a selective dose- and time-dependent decrease in survival of temozolomide-treated EGFR+ human-derived glioblastoma CSCs, which occurred through inhibition of NF-κB transcriptional activity. In addition, reduction in EGFR-amplified cells, along with a statistically significant decrease in NF-κB/p65 expression, were observed in specimens from recurrent metronomic-treated EGFR-overexpressing GBM patients. EGFR-amplified/overexpressing glioblastomas strongly benefit from metronomic temozolomide–based therapies.Keywords
This publication has 28 references indexed in Scilit:
- Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiformeNeuro-Oncology, 2013
- Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationBMC Medicine, 2012
- Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide EraPLOS ONE, 2012
- Nuclear PKM2 regulates β-catenin transactivation upon EGFR activationNature, 2011
- NFKBIADeletion in GlioblastomasNew England Journal of Medicine, 2011
- Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growthProceedings of the National Academy of Sciences, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2009
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003